Mehdi Rashighi, EADV 2020 – JAK inhibitors in Vitiligo
We were delighted to catch up with Mehdi Rashighi (University of Massachusetts Medical School, Boston, MA, USA) to discuss the use of JAK inhibitors in the treatment of vitiligo.
- What are the limitations of current therapeutic approaches for vitiligo? (0:26)
- What is the role of the JAK pathway in the pathogenesis of vitiligo? (0:56)
- What clinical evidence supports the use of JAK inhibitors in vitiligo? (1:51)
- What have been the long-term safety findings of clinical trials to date? (3:00)
- Which patients with vitiligo are likely to benefit most from JAK inhibitors and in whom are they contraindicated? (4:40)
Disclosures: In this interview, Mehdi Rashighi discusses unapproved uses of approved products. He was advised by Touch Medical Media to ensure that he disclosed any such references made to unlabelled or unapproved use. No endorsement by Touch Medical Media of any unapproved products or unapproved uses is either made or implied by the mention of these products.
Mehdi Rashighi is the Principal Investigator of studies sponsored by Target RWE and LEO Pharma. He is also Co-Investigator of studies sponsored by Pfizer, Sanofi, Incyte, and Dermavant and serves as an Editorial Board Member of FASEB, Frontiers in Immunology, and VisualDx.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the EADV 2020 Virtual Congress.
Share this Video
Related Videos In Vitiligo
Amit G. Pandya, Dermatology Meeting News 2023: Efficacy & safety of ruxolitinib cream in vitiligo – findings from the TRuE-V phase 3 studies
TRuE-V1 (NCT04052425) and TRuE-V2 (NCT04057573) were randomized, double-blind, vehicle-controlled phase 3 studies that investigated ruxolinitib cream for the treatment of vitiligo over 52 weeks. We were delighted to speak to Dr. Amit G. Pandya (Palo Alto Foundation Medical Group, Sunnyvale, CA, USA) around the efficacy and safety findings from the TRuE-V phase 3 studies and […]
Amit G. Pandya, Dermatology Meeting News 2023: JAK inhibitors for the treatment of vitiligo
Ruxolitinib cream, a cream formulation of the JAK 1/JAK2 inhibitor was first approved for use in vitiligo by the FDA in July 2022 and is the only topical treatment approved for repigmentation. We were delighted to speak to Dr. Amit G. Pandya (Palo Alto Foundation Medical Group, Sunnyvale, CA, USA) around the rationale and adverse […]
Thierry Passeron, EADV 2022: Efficacy of Ruxolitinib Cream by Body Region in Vitiligo – A Pooled Analysis of the TRuE-V Phase 3 Studies
TRuE-V1 (NCT04052425) and TRuE-V2 (NCT04057573) were randomized, double-blind, vehicle-controlled phase 3 studies investigating ruxolitinib cream in adults and adolescents with vitiligo. touchIMMUNOLOGY were delighted to speak with Prof. Thierry Passeron (University Hospital of Nice, Nice, France) to discuss the rationale and findings from his pooled analysis looking at the effect of ruxolitinib cream on achievement […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!